MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 02-21-2026
BeyondSpring Operating Income 2011-2026 | BYSI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income BeyondSpring
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.75 M | -15.1 M | -37.2 M | -66.2 M | -64.2 M | -40.3 M | -57.5 M | -98 M | -12.4 M | -7.48 M | -2.11 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.11 M | -98 M | -37.2 M |
Quarterly Operating Income BeyondSpring
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.79 M | -1.95 M | -2.61 M | - | -2.36 M | -2.64 M | -2.06 M | - | - | - | - | - | -18.3 M | -20 M | -17.4 M | - | -15.3 M | -13.6 M | -16.6 M | - | -9.7 M | -7.35 M | -7.97 M | - | -15.7 M | -12.4 M | -14.8 M | - | -18.6 M | -15 M | -47.8 M | - | -3.28 M | - | -1.92 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.79 M | -47.8 M | -11.7 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
-156 M | $ 2.11 | -13.17 % | $ 217 M |  USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
55.4 M | $ 20.52 | -2.12 % | $ 2.59 B | USA |
 |
Axsome Therapeutics
AXSM
|
-167 M | $ 164.13 | 0.15 % | $ 8.17 B | USA |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.49 | -3.11 % | $ 15.6 M | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
BridgeBio Pharma
BBIO
|
-523 M | $ 64.24 | -3.37 % | $ 12.3 B | USA |
 |
BioAtla
BCAB
|
-130 M | $ 0.18 | -26.92 % | $ 8.6 M | USA |
 |
BioCardia
BCDA
|
-11.6 M | $ 1.37 | 6.2 % | $ 29 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-2.54 M | $ 8.61 | -1.66 % | $ 1.78 B | USA |
 |
Black Diamond Therapeutics
BDTX
|
-78.8 M | $ 2.4 | -3.04 % | $ 132 M | USA |
 |
Beam Therapeutics
BEAM
|
-384 M | $ 28.29 | -0.6 % | $ 2.8 B | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-704 M | $ 11.47 | -0.43 % | $ 742 M | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Biogen
BIIB
|
7.04 B | $ 187.68 | -2.16 % | $ 27.5 B | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
BioVie
BIVI
|
-18.1 M | $ 1.38 | -0.01 % | $ 2.04 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-24.8 M | $ 2.91 | 2.83 % | $ 908 M |  Israel |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
409 M | $ 60.68 | -1.7 % | $ 11.6 B | USA |
 |
Benitec Biopharma
BNTC
|
-9.83 M | $ 10.85 | -0.5 % | $ 447 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 109.85 | -0.34 % | $ 27.2 B | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-67.2 M | $ 1.63 | -2.69 % | $ 4.13 M | USA |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 8.6 | 1.9 % | $ 1.39 B | Britain |
 |
Athira Pharma
ATHA
|
-101 M | - | - | $ 269 M | USA |